Azelastine + fluticasone

Trade Name:

Dymista

Manufacturer/Distributor:

BGP Pharma Inc.

Canadian Distrubutor: Mylan

Classification:

Antihistamine and corticosteroid agent

ATC Class:

R01AD58 - fluticasone, combinations

Status:

active

Notice of Compliance (yyyy/mm/dd):

2015/10/22

Date Marketed in Canada (yyyy/mm/dd):

2015/10/22

Presentation:

Nasal spray: 137 mcg azelastine and 50 mcg fluticasone per metered spray. DIN: 02432889

Further Information:

Used for the symptomatic treatment of moderate to severe seasonal allergic rhinitis and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient.

Keywords:

azelastine

Keywords:

fluticasone propionate

Keywords:

rhinitis: allergic

Keywords:

antihistamines

Keywords:

corticosteroids

Keywords:

intranasal drug administration

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Doravirine + Lamivudine + Tenofovir	Delstrigo	Antiviral agent	2018/12/15
Doripenem	Doribax	Antibacterial agent	2009/09
Doxepin	Silenor	Hypnotic	2012/01/08
Dronabinol	Marinol	Antiemetic	2012/02/24
Dronedarone	Multaq	Antiarrhythmic agent	2009/08/14
Drospirenone + estetrol	Nextstellis	Oral contraceptive	2021/06/15
Drotrecogin alfa	Xigris	Antithrombotic profibrinolytic anti-inflammatory enzyme	2011/10/25
Dulaglutide	Trulicity	Antihyperglycemic agent	2016/01/08
Dupilumab	Dupixent	Skin and mucous membrane agent	2017/11/30
Dutasteride + tamsulosin	Jalyn	Alpha-1 blocker + 5-Alpha reductase inhibitor	2012/02/03
Eculizumab	Soliris	Humanized monoclonal antibody	2009/06/29
Edaravone	Radicava	Treatment for amyotrophic lateral sclerosis	2019/10/29
Edoxaban	Lixiana	Anticoagulant	2017/01
Elagolix	Orilissa	Gonadotropin releasing hormone receptor antagonist	2018/10/31
Elbasvir + grazoprevir	Zepatier	Antiviral agent	2016/02/02
Elexacaftor + tezacaftor + ivacaftor	Trikafta	Cystic fibrosis transmembrane conductance regulator correctors	2021/06/22
Eltrombopag	Revolade	Thrombopoietin receptor antagonist	2011/0404
Eluxadoline	Viberzi	Miscellaneous GI drug	2017/05
Eluxadoline	Viberzi	Miscellaneous GI drugs	2017/04/24
Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide	Genvoya	Antiretroviral agents	2016/02/03
Elvitegravir + Cobicistat + Emtricitabine + Tenofovir disoproxil fumarate	Stribild	Antiretroviral agent	2012/12/20
Empagliflozin	Jardiance	Sodium-glucose contransporter 2 (SGLT2) inhibitor	2015/08/11
Empagliflozin + linagliptin	Glyxambi	Antidiabetic agent	2016/12/15
Empagliflozin + metformin	Synjardy	Oral blood glucose lowering agents	2017/09/18
Emtricitabine + tenofovir	Descovy	Antiretroviral agent	2016/06/03
Enasidenib	IDHIFA	Antineoplastic agent / IDH2 Inhibitor	2019/02/27
Entrectinib	Rozlytrek	Antineoplastic agent
Enzalutamide	Xtandi	Antineoplastic agent	2013/06/07
Eplerenone	Inspra	Aldosterone antagonist	2009/02/26
Eptinezumab	Vyepti	Prevention of migraine; calcitonin gene-related peptide binding antibody	2021/01/11
Erdafitinib	Balversa	Protein kinase inhibitor	2019/12/09
Erenumab	Aimovig	Anti-calcitonin gene-related peptide receptor	2018/08/01
Eribulin	Halaven	Antineoplastic agent	2012/03/10
Ertugliflozin	Steglatro	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	2018/05/23
Ertugliflozin + metformin	Segluromet	Oral blood glucose lowering agents	2018/05/30
Ertugliflozin + sitagliptin	Steglujan	Oral blood glucose lowering agents	2018/05/22